With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.226942-29-6,6-Bromo-1,2,3,4-tetrahydroisoquinoline,as a common compound, the synthetic route is as follows.
To a mixture of 4-(2-chloro-4-pyrimidinyl)mophiholine (910 mg, 4.56 mmol) and 6-bromo-l,2,3,4- tetrahydroisoquinoline (967 mg, 4.56 mmol) is added anhydrous NMP (12 mL) and the reaction is flushed well with nitrogen. The reaction is then treated with NN- diisopropylethylamine (2.0 mL, 11.45 mmol), capped and placed in a 120 C oil bath for 16 hours. Crude LC/MS seems to indicate complete conversion to the desired product. Removed NuMuRho and Hunig’s base under a stream of nitrogen while heating at 80 C overnight. A yellow solid remained. Took up the solid in EtOAc, heated to dissolve most material in minimum amount of solvent, filtered while hot, allow to cool to RT slowly to give 1.65g (91%) of 4-(2-(6-bromo-3,4-dihydroisoquinolin-2(lH)-yl)pyrimidin-4- yl)morpholine as a pale yellow solid as recrystallized material. LCMS (M+l) = 374.7 and (0235) 376.7., 226942-29-6
The synthetic route of 226942-29-6 has been constantly updated, and we look forward to future research findings.
Reference£º
Patent; VIIV HEALTHCARE UK (NO.5) LIMITED; BOWSHER, Michael S.; DESKUS, Jeffrey; EASTMAN, Kyle J.; GILLIS, Eric P; FRENNESSON, David B; IWUAGWU, Christiana; NAIDU, B. Narasimhulu; PARCELLA, Kyle E.; PEESE, Kevin M; SAULNIER, Mark G; SIVAPRAKASAM, Prasanna; (220 pag.)WO2018/127801; (2018); A1;,
Tetrahydroisoquinoline – Wikipedia
1,2,3,4-Tetrahydroisoquinoline | C9H11N – PubChem